Lexeo Therapeutics Inc [LXEO] stock is trading at $4.61, down -2.54%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LXEO shares have gain 11.62% over the last week, with a monthly amount glided 5.25%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on July 31, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $20. Previously, Robert W. Baird started tracking the stock with Outperform rating on June 13, 2024, and set its price target to $28. On June 06, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $22 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $20 on November 28, 2023. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $22 as its price target on November 28, 2023. Leerink Partners started tracking with a Outperform rating for this stock on November 28, 2023, and assigned it a price target of $19. In a note dated November 28, 2023, JP Morgan initiated an Overweight rating and provided a target price of $20 on this stock.
Lexeo Therapeutics Inc [LXEO] stock has fluctuated between $1.45 and $13.63 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $4.61 at the most recent close of the market. An investor can expect a potential return of 507.38% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.87, Equity is -0.86 and Total Capital is -1.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.33 points at the first support level, and at 4.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.83, and for the 2nd resistance point, it is at 5.06.
Ratios To Look Out For
For context, Lexeo Therapeutics Inc’s Current Ratio is 3.42. Also, the Quick Ratio is 3.42, while the Cash Ratio stands at 0.94.
Transactions by insiders
Recent insider trading involved Townsend Richard Nolan, Chief Executive Officer, that happened on May 16 ’25 when 1074.0 shares were sold. Chief Medical Officer, Adler Eric completed a deal on May 16 ’25 to sell 585.0 shares. Meanwhile, Chief Legal Officer Robertson Jenny sold 521.0 shares on May 16 ’25.
